News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Evandro de Azambuja: Overall Survival Benefit with Adjuvant Trastuzumab and Pertuzumab in Aphinity
Evandro de Azambuja/LinkedIn
May 17, 2025, 14:49

Evandro de Azambuja: Overall Survival Benefit with Adjuvant Trastuzumab and Pertuzumab in Aphinity

Evandro de Azambuja, Director of Membership 2023-2025 at ESMO – European Society for Medical Oncology, shared on LinkedIn:

“Overall Survival benefit with adjuvant trastuzumab and pertuzumab in Aphinity (node positive with absolute benefit of 2.7%)! All those years of hard work are translating into improved patients outcomes!”

Evandro de Azambuja

Read this article about Breast Cancer on OncoDaily.

Evandro de Azambuja

APHINITY cancer ESMO Evandro de Azambuja OncoDaily Oncology overall survival patients outcomes
Special Coverage
Blog
May 17, 2025, 14:49
Evandro de Azambuja: Overall Survival Benefit with Adjuvant Trastuzumab and Pertuzumab in Aphinity
Blog
May 17, 2025, 14:11
Danny Burke: Clinicopathological Insights into Advanced Acral Melanoma - A Peruvian Perspective
Blog
May 17, 2025, 13:47
Rasha Aboelhassan: From screening to early diagnosis and treatments at ESMO Breast 2025
Insight
May 17, 2025, 12:46
Key Takeaways from ACS CAN’s 2025 National Forum on the Future of Healthcare
Blog
May 17, 2025, 12:40
Partha Basu: CanScreen5 Webinar Series Focuses on Improving Cancer Control Programs in the Asia-Pacific Region
Blog
May 17, 2025, 12:40
Petros Grivas Prepares for Annual BCAN Walk in Seattle
Blog
May 17, 2025, 12:34
U.S. FDA will Host Independent and Scientific Expert Panel Open to Public
Blog
May 17, 2025, 12:24
Mark Yarchoan: Recent Advances in Therapeutic Cancer Vaccines
Blog
May 17, 2025, 12:16
Luis Lara-Mejía: Early Resistance in ALK+ NSCLC Targeted with Alectinib and Bevacizumab Combo
Blog
May 17, 2025, 12:09
Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC
Blog
May 17, 2025, 11:55
Jordi Remon Highlights EORTC Lung Cancer Group’s Spring Meeting in Genova
Science
May 17, 2025, 11:48
Raffaele Colombo: The Therapeutic Window of Antibody-Drug Conjugates